On the cause and consequences of IgE to galactose-?-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy - 06/04/20
, Scott P. Commins, MD, PhD b, Tilo Biedermann, MD c, Marianne van Hage, MD, PhD d, Michael Levin, MD, PhD e, Lisa A. Beck, MD f, Maria Diuk-Wasser, PhD g, Uta Jappe, MD, MSc h, i, ∗, Danijela Apostolovic, PhD d, Michael Minnicozzi, PhD j, Marshall Plaut, MD j, Jeffrey M. Wilson, MD, PhD aAbstract |
The mammalian meat allergy known as the “α-Gal syndrome” relates to IgE specific for galactose-α-1,3-galactose (α-Gal), an oligosaccharide that is present in cells and tissues of nonprimate mammals. The recognition of delayed reactions to food derived from mammals in patients with IgE to α-Gal and also the association with tick bites have been increasing worldwide. In 2018, the National Institute of Allergy and Infectious Diseases, Division of Allergy, Immunology and Transplantation, sponsored a workshop on this emerging tick-related disease. International experts from the fields of tick biology, allergy, immunology, infectious disease, and dermatology discussed the current state of our understanding of this emerging medical condition. The participants provided suggestions for specific research priorities and for the development of resources to advance our knowledge of the mechanisms, diagnosis, management, and prevention of this allergic disease. This publication is a summary of the workshop and the panel’s recommendations are presented herein.
Le texte complet de cet article est disponible en PDF.Key words : α-Gal, anaphylaxis, IgE, oligosaccharide allergen, glycolipids, mammalian meat allergy, ticks
Abbreviations used : AGS, α-Gal, CDC, RMSF
Plan
| Disclosure of potential conflict of interest: T. A. E. Platts-Mills was supported by the National Institutes of Health (NIH) (grant no. R37-AI-20565); has received assay support from Thermo Fisher/Phadia; and has a patent on an IgE assay to α-Gal. S. P. Commins was supported by the NIH (grant nos. R01AI135049, R56AI113095, and K08AI85190) and the Centers for Disease Control and Prevention (grant no. IPA1908943); has been on the speaker’s bureau at Genentech; and has received author royalties from Up-to-Date. M. van Hage reports grants from H2020 FoodEnTwin GA (no. 810752), the Swedish Research Council, the Stockholm County Council (ALF project), the Swedish Asthma and Allergy Association’s Research Foundation, the King Gustaf V 80th Birthday Foundation, the Swedish Heart-Lung Foundation, the Hesselman Foundation, the Swedish Cancer and Allergy Foundation, and the Swedish Association for Allergology; personal fees from Biomay AG, Vienna, Austria, and Hycor Biomedical LLC, Calif; and personal fees from Thermo Fisher Scientific and ALK, outside the submitted work; L. A. Beck is a consultant or Advisory Board Member for Abbvie, Allakos, Arena Pharma, Astra-Zeneca, Connect Biopharma, LEO Pharma, Lilly, Novan, Novartis, Pfizer, Regeneron, Sanofi, UCB, and Vimalan; is or has recently been an investigator for an Abbvie, LEO Pharma, Pfizer, and/or Regeneron clinical trial; and owns stock in Pfizer and Medtronics. D. Apostolovic reports grants from H2020 FoodEnTwin GA (no. 810752) and from Konsul Th C Berg Foundation, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 145 - N° 4
P. 1061-1071 - avril 2020 Retour au numéro
Article précédent
- Epigenetic factors involved in the pathophysiology of inflammatory skin diseases
- Lena Möbus, Stephan Weidinger, Hila Emmert
- Summary of the Keystone Symposium “Origins of allergic disease: Microbial, epithelial and immune interactions,” March 24-27, Tahoe City, California
- Rosemarie H. DeKruyff, Wenming Zhang, Kari C. Nadeau, Donald Y.M. Leung, Marsha Wills-Karp
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?